

Table 2- VIP and VIM studies: percentage of eyes with loss <3 lines in the ETDRS chart.

Table 2- VIP and VIM studies: percentage of eyes with loss <3 lines in the ETDRS chart.

Study	MTRI verteporfin	MTRI Placebo	p
VIP 12 months	49%	45%	Ns
VIP 24 months	45%	32%	0.032
VIM 12 months 300 mw/cm ²	86%	53%	0.002
VIM 12 Months 600 mw/cm ²	72%	53%	0.08
VIM 24 months 300 mwcm ²	74%	38%	0.003

VIM 24 months 600 mwcm ²	47%	38%	0.45
--	-----	-----	------

[View PDF](#)